25 results
424B5
RPTX
Repare Therapeutics Inc
4 Aug 22
Prospectus supplement for primary offering
5:00pm
and tolerability of RP-6306 in combination with gemcitabine and, in January 2022, we initiated patient recruitment in our MINOTAUR clinical trial to evaluate … the safety and tolerability of RP-6306 in combination with folfiri. In addition, in May 2022, we initiated patient recruitment in a new arm of our
8-K
EX-99.1
50ny1wv8 a59v
4 Aug 22
Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
4:14pm
8-K
EX-99.1
b2yxh
13 May 21
Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
4:45pm
DEF 14A
ds1i81
1 Apr 21
Definitive proxy
7:36am
10-K
vys k98j27bm2o4aydfd
4 Mar 21
Annual report
5:25pm
8-K
EX-99.1
enexvp16
4 Mar 21
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
5:24pm
10-Q
h0lrb274
13 Aug 20
Quarterly report
4:12pm
424B4
f2bfyzvnojxeg
19 Jun 20
Prospectus supplement with pricing info
4:38pm